MA32731B1 - Céphalosporine possédant un groupe catéchol - Google Patents

Céphalosporine possédant un groupe catéchol

Info

Publication number
MA32731B1
MA32731B1 MA33798A MA33798A MA32731B1 MA 32731 B1 MA32731 B1 MA 32731B1 MA 33798 A MA33798 A MA 33798A MA 33798 A MA33798 A MA 33798A MA 32731 B1 MA32731 B1 MA 32731B1
Authority
MA
Morocco
Prior art keywords
similar
cepham compound
protected
ester
substituted
Prior art date
Application number
MA33798A
Other languages
Arabic (ar)
English (en)
Inventor
Yasuhiro Nishitani
Kenji Yamawaki
Yusuke Takeoka
Hideki Sugimoto
Shinya Hisakawa
Toshiaki Aoki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42128829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32731(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MA32731B1 publication Critical patent/MA32731B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ DE CÉPHÈME REPRÉSENTÉ PAR LA FORMULE (I) [DANS LAQUELLE X REPRÉSENTE N, CH OU C-CL ; T REPRÉSENTE S OU SIMILAIRE ; A ET G REPRÉSENTENT INDÉPENDAMMENT UN ALKYLÈNE INFÉRIEUR OU SIMILAIRE ; B REPRÉSENTE UNE SIMPLE LIAISON OU SIMILAIRE ; D REPRÉSENTE UNE SIMPLE LIAISON, -NR7-CO-, -CO-NR7-, 'NR7-CO-NR7- OU SIMILAIRE ; E REPRÉSENTE UN ALKYLÈNE INFÉRIEUR QUI PEUT ÊTRE SUBSTITUÉ ; F REPRÉSENTE UNE SIMPLE LIAISON OU UN PHÉNYLÈNE QUI PEUT ÊTRE SUBSTITUÉ ; R3, R4, R5 ET R6 REPRÉSENTENT CHACUN INDÉPENDAMMENT UN HYDROGÈNE, UN HALOGÈNE, UN NITRILE OU 'OR8 ; R8 REPRÉSENTE UN HYDROGÈNE OU SIMILAIRE ; ET UN GROUPE REPRÉSENTÉ PAR LA FORMULE (II) REPRÉSENTE UN GROUPE AMMONIUM QUATERNAIRE MONOCYCLIQUE OU À CYCLES CONDENSÉS SATURÉ OU INSATURÉ QUI POSSÈDE AU MOINS UN ATOME N ET QUI PEUT ÊTRE SUBSTITUÉ, LA LIGNE TIRETÉE REPRÉSENTANT UNE LIAISON DANS LE CYCLE], UN ESTER DU COMPOSÉ DE CÉPHÈME, UN PRODUIT PROTÉGÉ DU COMPOSÉ DE CÉPHÈME DANS LEQUEL UN GROUPE AMINO, SITUÉ SUR LE NOYAU DANS LA CHAÎNE DU CÔTÉ DE LA POSITION 7, EST PROTÉGÉ, UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DU COMPOSÉ DE CÉPHÈME, DE L'ESTER OU DU PRODUIT PROTÉGÉ, OU UN SOLVATE DU COMPOSÉ DE CÉPHÈME, DE L'ESTER, DU PRODUIT PROTÉGÉ OU DU SEL PHARMACEUTIQUEMENT ACCEPTABLE, QUI PRÉSENTE UN LARGE SPECTRE ANTIBACTÉRIEN ET EN PARTICULIER QUI PRÉSENTE UNE ACTIVITÉ ANTIBACTÉRIENNE PUISSANTE VIS-À-VIS DE BACTÉRIES À GRAM NÉGATIF PRODUISANT DE LA ß-LACTAMASE. L'INVENTION PORTE ÉGALEMENT SUR UNE COMPOSITION PHARMACEUTIQUE RENFERMANT LE COMPOSÉ DE CÉPHÈME, L'ESTER, LE PRODUIT PROTÉGÉ, LE SEL PHARMACEUTIQUEMENT ACCEPTABLE OU LE SOLVATE.
MA33798A 2008-10-31 2011-04-29 Céphalosporine possédant un groupe catéchol MA32731B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008280828 2008-10-31
PCT/JP2009/068400 WO2010050468A1 (fr) 2008-10-31 2009-10-27 Céphalosporine possédant un groupe catéchol

Publications (1)

Publication Number Publication Date
MA32731B1 true MA32731B1 (fr) 2011-10-02

Family

ID=42128829

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33798A MA32731B1 (fr) 2008-10-31 2011-04-29 Céphalosporine possédant un groupe catéchol

Country Status (38)

Country Link
US (1) US9238657B2 (fr)
EP (2) EP2960244B1 (fr)
JP (2) JP5498393B2 (fr)
KR (1) KR101655961B1 (fr)
CN (1) CN102203100B (fr)
AU (1) AU2009310959B2 (fr)
BR (1) BRPI0921701B8 (fr)
CA (1) CA2736953C (fr)
CL (1) CL2011000939A1 (fr)
CO (1) CO6331443A2 (fr)
CR (1) CR20110144A (fr)
CY (2) CY1118536T1 (fr)
DK (1) DK2960244T3 (fr)
EA (1) EA019520B1 (fr)
ES (2) ES2564836T3 (fr)
FI (1) FIC20200039I1 (fr)
FR (1) FR20C1050I2 (fr)
HR (1) HRP20161408T1 (fr)
HU (2) HUE031802T2 (fr)
IL (1) IL211720A (fr)
LT (2) LT2960244T (fr)
MA (1) MA32731B1 (fr)
ME (1) ME02666B (fr)
MX (1) MX2011004636A (fr)
MY (1) MY155655A (fr)
NL (1) NL301067I2 (fr)
NO (1) NO2020035I1 (fr)
NZ (1) NZ591728A (fr)
PE (1) PE20120010A1 (fr)
PL (1) PL2960244T3 (fr)
PT (1) PT2960244T (fr)
RS (1) RS55365B1 (fr)
SI (1) SI2960244T1 (fr)
SM (1) SMT201600397B (fr)
TW (1) TWI535727B (fr)
UA (1) UA105190C2 (fr)
WO (1) WO2010050468A1 (fr)
ZA (1) ZA201102024B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009049086A1 (fr) 2007-10-09 2009-04-16 Larry Sutton Inhibiteurs de bêta-lactamase à large spectre
MX2011004636A (es) * 2008-10-31 2011-06-20 Shionogi & Co Cefarosporinas que tienen un grupo catecol.
US8883773B2 (en) 2010-04-05 2014-11-11 Shionogi & Co., Ltd. Cephem compound having pseudo-catechol group
EP2557082A4 (fr) * 2010-04-05 2013-08-28 Shionogi & Co Composé de céphème comprenant un groupe catéchol
JP5852562B2 (ja) * 2010-04-28 2016-02-03 塩野義製薬株式会社 新規なセフェム誘導体
EP2681196B1 (fr) 2011-03-04 2015-09-09 Life Technologies Corporation Composés et procédés de conjugaison de biomolécules
KR101719556B1 (ko) * 2011-03-30 2017-03-24 주식회사 레고켐 바이오사이언스 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물
US9334289B2 (en) * 2011-04-28 2016-05-10 Shionogi & Co., Ltd. Cephem compound having catechol or pseudo-catechol structure
CN103619853A (zh) 2011-06-27 2014-03-05 盐野义制药株式会社 具有吡啶鎓基的头孢烯化合物
US9290515B2 (en) 2011-10-04 2016-03-22 Shionogi & Co., Ltd Cephem derivative having catechol group
TWI547496B (zh) 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
AU2013339040A1 (en) 2012-10-29 2015-04-30 Shionogi & Co., Ltd. Processes for production of intermediates for 2-alkyl cephem compounds
US20150344502A1 (en) * 2012-12-26 2015-12-03 Shionogi & Co., Ltd. Cephem compound
WO2015035376A2 (fr) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Traitement d'infections au moyen de ceftolozane/tazobactam chez des sujets ayant une fonction rénale altérée
CN106164072B (zh) 2014-03-24 2019-10-01 诺华股份有限公司 用于治疗细菌感染的单环内酰胺有机化合物
JP6377570B2 (ja) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２−置換セフェム化合物を含有する医薬組成物
ES2874579T3 (es) 2014-06-11 2021-11-05 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
DK3190115T3 (da) * 2014-09-04 2021-10-25 Shionogi & Co Salt af cephalosporinderivat, krystallinsk fast form deraf og fremgangsmåde til fremstilling deraf
WO2016035847A1 (fr) * 2014-09-04 2016-03-10 塩野義製薬株式会社 Intermédiaire de dérivés de céphalosporine et son procédé de production
WO2016035846A1 (fr) * 2014-09-04 2016-03-10 塩野義製薬株式会社 Préparation pharmaceutique comprenant une céphalosporine ayant des groupes catéchol
WO2016198691A1 (fr) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Inhibiteurs de la pompe à efflux et utilisations thérapeutiques correspondantes
ES2817537T3 (es) 2015-09-23 2021-04-07 Novartis Ag Sales y formas sólidas de un antibiótico monobactámico
WO2017096472A1 (fr) * 2015-12-10 2017-06-15 Naeja-Rgm Pharmaceuticals Inc. Composés de céphème, leur préparation et utilisation
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
MX2018014813A (es) * 2016-06-17 2019-03-14 Wockhardt Ltd Composiciones antibacterianas.
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
KR102694317B1 (ko) * 2017-06-09 2024-08-09 포브 신서시스 인코포레이티드 세균 감염의 치료를 위한 카바페넴 화합물 및 조성물
ES2912656T3 (es) 2017-08-02 2022-05-26 Novartis Ag Proceso para preparar ácido 1-(((Z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoacetidin-3-il)amino)etiliden)amino)oxi)ciclopropano carboxílico
EA202091696A1 (ru) 2018-02-28 2021-01-27 Новартис Аг ПРОИЗВОДНЫЕ 10-(ДИ(ФЕНИЛ)МЕТИЛ)-4-ГИДРОКСИ-8,9,9a,10-ТЕТРАГИДРО-7H-ПИРРОЛО[1',2':4,5]ПИРАЗИНО[1,2-b]ПИРИДАЗИН-3,5-ДИОНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ РЕПЛИКАЦИИ ОРТОМИКСОВИРУСА ДЛЯ ЛЕЧЕНИЯ ГРИППА
EP3802551A4 (fr) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Inhibiteurs de protéine de liaison à la pénicilline
WO2020184399A1 (fr) * 2019-03-08 2020-09-17 塩野義製薬株式会社 Composition pharmaceutique antibactérienne
US12371441B2 (en) 2019-09-06 2025-07-29 Ariva Med Gmbh Siderophore cephalosporin conjugates and uses thereof
MX2022008470A (es) * 2020-01-22 2022-08-02 Shanghai Senhui Medicine Co Ltd Compuesto antibacteriano de cefalosporina y aplicacion farmaceutica del mismo.
TW202220663A (zh) 2020-07-28 2022-06-01 日商鹽野義製藥股份有限公司 含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法
KR20230131292A (ko) * 2021-01-12 2023-09-12 상하이 센후이 메디슨 컴퍼니 리미티드 세팔로스포린 항균 화합물 및 이의 제조 방법
CN113698365A (zh) * 2021-08-30 2021-11-26 成都大学 一种头孢地尔侧链的制备方法
TW202448477A (zh) 2023-06-01 2024-12-16 大陸商江蘇恆瑞醫藥股份有限公司 一種包含頭孢類抗菌化合物的醫藥組成物
CN117024377B (zh) * 2023-08-15 2025-04-29 济南大学 一种2-氯-3,4-二对甲氧苯甲氧基-n-(2-(1-吡咯烷)乙基)苯甲酰胺的制备方法
CN117069638B (zh) * 2023-08-17 2026-02-27 济南大学 一种头孢地尔中间体的制备方法
CN117088764B (zh) * 2023-08-24 2026-01-30 济南大学 一种头孢地尔关键中间体的合成和后处理方法
US12225906B1 (en) 2024-09-26 2025-02-18 Terry Earl Brady Pathogenic affinity pathway of infectious or parasitic organisms for nanogram and picogram dosimetry prophylaxis or cure

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
JPS57118588A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel cephalosporin
DE3207840A1 (de) 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
AU2361184A (en) 1983-01-21 1984-07-26 Beecham Group Plc Disubstituted 6-penicillins and 7-cephalosporins
NO165842C (no) 1984-04-23 1991-04-17 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
EP0168177A3 (fr) 1984-06-28 1987-04-01 Pfizer Limited Céphalosporines antibiotiques
EP0203271B1 (fr) 1985-03-01 1993-05-26 Takeda Chemical Industries, Ltd. Composés antibactériens, leur préparation et leur utilisation
JPH068300B2 (ja) * 1985-08-02 1994-02-02 萬有製薬株式会社 新規セフアロスポリン誘導体
EP0211656A3 (fr) 1985-08-10 1988-03-09 Beecham Group Plc Dérivés de céphalosporine, procédé pour leur préparation et les compositions pharmaceutiques les contenant
EP0214600B1 (fr) * 1985-09-03 1992-12-02 Otsuka Kagaku Kabushiki Kaisha Dérivés de céphalosporine
JPH07107069B2 (ja) * 1985-09-03 1995-11-15 大塚化学株式会社 セフアロスポリン化合物の新規誘導体、その製造法及び該誘導体を含有する医薬組成物
JPS62158291A (ja) 1986-01-07 1987-07-14 Sagami Chem Res Center セフアロスポリン誘導体
US5084453A (en) * 1986-04-14 1992-01-28 Banyu Pharmaceutical Co., Ltd. 1-carboxy-1-vinyloxyimino aminothiazole cephalosporin derivatives
EP0241901B1 (fr) 1986-04-14 1994-08-24 Banyu Pharmaceutical Co., Ltd. Dérivés de céphalosporine, leurs procédés de préparation et agents antibactériens
IE61679B1 (en) * 1987-08-10 1994-11-16 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
GB8719875D0 (en) 1987-08-22 1987-09-30 Beecham Group Plc Compounds
JPH0228185A (ja) * 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
GB8811055D0 (en) 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
US5149803A (en) * 1988-05-10 1992-09-22 Imperial Chemical Industries Plc Intermediates for cephalosporin compounds
US5244890A (en) * 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
PH25965A (en) * 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
GB8813945D0 (en) * 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) * 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
CA2005787A1 (fr) 1988-12-29 1990-06-29 Masao Wada Composes de cephalosporine
JPH02275886A (ja) 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
US5143910A (en) 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5126336A (en) * 1990-08-23 1992-06-30 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
US5095012A (en) 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5234920A (en) 1990-08-23 1993-08-10 Bristol-Myers Squibb Company Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5194433A (en) * 1990-11-13 1993-03-16 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
EP0628562A1 (fr) 1993-06-10 1994-12-14 Roussel Uclaf Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments
AU1694099A (en) 1997-12-26 1999-07-19 Cheil Jedang Corporation Cephem derivatives and a method for producing the compounds and an antibacterialcomposition containing the compounds
EP1379523B1 (fr) 2001-03-27 2005-07-27 Actelion Pharmaceuticals Ltd. Derives de 1,2,3,4-tetrahydro-isoquinoline en tant qu'antagonistes du recepteur de l'urotensine ii
JP2003078440A (ja) 2001-08-30 2003-03-14 Kyocera Corp 高周波スイッチ回路
TW200305422A (en) 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
WO2003099826A1 (fr) 2002-05-23 2003-12-04 Orchid Chemicals And Pharmaceuticals Limited Nouvelle methode de preparation de cefditorene utilisant le thioester d'acide thiazolylacetique
JP4892926B2 (ja) 2005-10-25 2012-03-07 宇部興産株式会社 スルホン化芳香族ブロック共重合体の製造方法
TW200637559A (en) 2005-03-29 2006-11-01 Shionogi & Co 3-propenylcefem derivative
JP4557859B2 (ja) 2005-09-29 2010-10-06 富士通株式会社 周波数分割多重送受信装置及び送受信方法
WO2007096740A2 (fr) 2006-02-20 2007-08-30 Orchid Research Laboratories Limited Nouvelles céphalosporines
WO2007119511A1 (fr) * 2006-03-16 2007-10-25 Astellas Pharma Inc. Composés de céphem et leur utilisation en tant qu'agents antimicrobiens
MX2011004636A (es) 2008-10-31 2011-06-20 Shionogi & Co Cefarosporinas que tienen un grupo catecol.
US8883773B2 (en) * 2010-04-05 2014-11-11 Shionogi & Co., Ltd. Cephem compound having pseudo-catechol group
EP2557082A4 (fr) * 2010-04-05 2013-08-28 Shionogi & Co Composé de céphème comprenant un groupe catéchol
JP5852562B2 (ja) * 2010-04-28 2016-02-03 塩野義製薬株式会社 新規なセフェム誘導体

Also Published As

Publication number Publication date
CY2020034I2 (el) 2021-05-05
EP2341053A1 (fr) 2011-07-06
US20110190254A1 (en) 2011-08-04
FR20C1050I1 (fr) 2020-11-27
ZA201102024B (en) 2014-08-27
IL211720A (en) 2015-01-29
LTPA2020530I1 (lt) 2020-11-10
NO2020035I1 (no) 2020-10-21
NL301067I1 (fr) 2020-10-13
MX2011004636A (es) 2011-06-20
EP2341053B1 (fr) 2016-01-13
EA201170632A1 (ru) 2011-12-30
CN102203100B (zh) 2014-08-27
EP2341053A4 (fr) 2012-08-08
MY155655A (en) 2015-11-13
DK2960244T3 (en) 2016-11-28
FR20C1050I2 (fr) 2021-10-15
CA2736953C (fr) 2017-07-11
WO2010050468A1 (fr) 2010-05-06
SI2960244T1 (sl) 2017-02-28
UA105190C2 (ru) 2014-04-25
CA2736953A1 (fr) 2010-05-06
LT2960244T (lt) 2016-11-25
ES2564836T3 (es) 2016-03-29
BRPI0921701B8 (pt) 2022-11-29
SMT201600397B (it) 2017-01-10
US9238657B2 (en) 2016-01-19
BRPI0921701B1 (pt) 2022-05-03
CN102203100A (zh) 2011-09-28
BRPI0921701A2 (pt) 2020-08-11
AU2009310959A1 (en) 2010-05-06
EA019520B1 (ru) 2014-04-30
TWI535727B (zh) 2016-06-01
JP5498393B2 (ja) 2014-05-21
LTC2960244I2 (lt) 2023-10-10
NL301067I2 (nl) 2020-10-28
EP2960244A1 (fr) 2015-12-30
EP2960244B1 (fr) 2016-09-14
CR20110144A (es) 2011-09-09
IL211720A0 (en) 2011-06-30
HUS2000042I1 (hu) 2020-11-30
AU2009310959B2 (en) 2015-05-07
CY2020034I1 (el) 2020-11-25
TW201020259A (en) 2010-06-01
CL2011000939A1 (es) 2011-09-16
PL2960244T3 (pl) 2017-03-31
JP2014065732A (ja) 2014-04-17
KR20110090982A (ko) 2011-08-10
FIC20200039I1 (fi) 2020-10-19
JPWO2010050468A1 (ja) 2012-03-29
ES2602969T3 (es) 2017-02-23
PE20120010A1 (es) 2012-02-07
PT2960244T (pt) 2016-11-02
HUE031802T2 (en) 2017-08-28
KR101655961B1 (ko) 2016-09-08
NZ591728A (en) 2012-12-21
CO6331443A2 (es) 2011-10-20
HRP20161408T1 (hr) 2016-12-02
RS55365B1 (sr) 2017-03-31
ME02666B (fr) 2017-06-20
CY1118536T1 (el) 2017-07-12

Similar Documents

Publication Publication Date Title
MA33893B1 (fr) Derives de diphenyl-pyrazolopyridines,leur preparation et leur appalication en therapeutique
MA37358A1 (fr) Composition de lutte antiparasitaire comprenant un nouveau dérivé d'iminopyridine
MA27119A1 (fr) Modulateurs tetrahydropyranyle cyclopentyle tetrahydropyrido pyridine de l'activite d'un recepteur de chimiokine
MA34551B1 (fr) Agent de lutte contre des organismes nuisibles
NO20075723L (no) Tiazolforbindelser og fremgangsmater for anvendelse
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
EA200500472A1 (ru) Ацетил 2-гидрокси-1,3-диаминоалканы
CA2203618A1 (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
MA27831A1 (fr) Procede pour preparer un analogue de la cyclosporine a
MA29323B1 (fr) Composes de l'acide pyridylacetique
MA30813B1 (fr) Derives de 2-pyridinecarboxamide ayant un effet d'activation sur la gk.
MA28453B1 (fr) Nouveaux insecticides
ATE312100T1 (de) Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten
MA32646B1 (fr) Compositions d'antagonistes de pd -1 et methodes d'utilisation associees
WO2005092858A3 (fr) Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
EA200500814A1 (ru) Производные пирролопиримидина
FR2926554B1 (fr) Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
EA201170632A1 (ru) Цефалоспорины, содержащие катехольную группу
WO2006113615A3 (fr) Agents antimicrobiens et utilisations de ceux-ci
WO2005030766A8 (fr) Composes phenyl-carboxamide utiles pour traiter la douleur
FR2426694A1 (fr) Cephalosporines perfectionnees, leur procede de preparation et leur application therapeutique
MA30540B1 (fr) Derives de quinolines et compositions pharmaceutiques de ces derives.
DK1961734T3 (da) Aminforbindelse og anvendelse deraf til medicinske formål
ATE450511T1 (de) Kristalline formen eines arylanilin-beta-2- adrenergenrezeptor-agonists